Carcinosarcoma

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 25, 2022
COVID-19, Technology, Research, Squamous cell carcinoma, Liver, Xi, Risk, Carcinosarcoma, U.S. Securities and Exchange Commission, SCC, 100,000, GLOBE, Company, Investor, PMDA, Prostate cancer, Vii, Alpha Tau Delta, Patient, Neoadjuvant therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, Food, SEC, Nasdaq, FDA, Environmental protection, Annual report, Trial of the century, KOL, D, Financial result, GBM, Skin cancer, IDE, Health Canada, D&O, Pancreatic tumor, BCC, Prostate, Private Securities Litigation Reform Act, Marketing, RECIST, Neoplasm, Ministry, XV, Alpha Sigma Tau, Pancreatic cancer, Neck, G&A, Medical device, Medical imaging, Pharmaceutical industry, Renewable energy, Alpha, Tel Aviv University

JERUSALEM, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2022 financial results and provided a corporate update.

Key Points: 
  • The Company expects to treat its first patient in this study later in 2022-
    JERUSALEM, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the Company), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported second quarter 2022 financial results and provided a corporate update.
  • First patient treated in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer.
  • Expecting first patient treated in U.S. multi-center pivotal trial in recurrent cutaneous SCC in the second half of 2022.
  • Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.

Global Endometrial Cancer Epidemiology Forecast to 2030 - Understanding the Trends Shaping and Driving the Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 23, 2021
Health, Women, Oncology, Consumer, Method, Uterus, POLE, CN, Risk, Carcinosarcoma, Biomarker, Endometrioid tumor, Population, Diagnosis, AGR, Woman, Uterine cancer, Microsatellite instability, Epidemiology, MSI, Endometrial cancer, Gynaecology, FIGO, List of international sports federations, II, Birth control, Dietary supplement, Vaccine

The "Endometrial Cancer - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endometrial Cancer - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Endometrial cancer is the most common form of uterine cancer, arising from the endometrial lining of the uterus.
  • When examining the AGR by individual market, The publisher forecasts that all markets will see an increase in the diagnosed incident cases of endometrial cancer during the forecast period.
  • The Endometrial Cancer Epidemiology Report provides an overview of the risk factors and global trends of endometrial cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada)
    It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of endometrial cancer in these markets from 2020-2030.

Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer

Retrieved on: 
Monday, March 18, 2019
Gynaecological cancer, Health, Sarcoma, Clinical medicine, Carcinosarcoma, Oncology, Gynecologic oncology, Uterine cancer, Epidemiology

CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer.

Key Points: 
  • CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer.
  • "We are also particularly interested in the early activity in carcinosarcoma patients, who are in need of new and better treatment options."
  • Carcinosarcoma partial response leads to new expansion cohort at higher dose:Carcinosarcoma is a rare and difficult-to-treat form of uterine cancer.
  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics.